Printer Friendly

Guidant Announces Enrollment Completion for Largest Clinical Trial to Study Right Ventricular Pacing.

INDIANAPOLIS, Ind. & ST. PAUL, Minn. -- Guidant Corporation (NYSE:GDT)

International Trial Will Study Unnecessary Pacing in Heart Failure Patients

Guidant Corporation (NYSE:GDT) today announced that it has completed enrollment in a major clinical trial to study unnecessary pacing in heart failure patients. Results from previous trials demonstrate that without careful attention to minimizing unnecessary right ventricular pacing the heart's natural rhythm may be disrupted with some patients experiencing worsened heart failure and increased hospitalizations.

The Guidant-sponsored trial is designed to demonstrate the efficacy and value of a proprietary feature that minimizes unnecessary right ventricular pacing in patients who received a Guidant dual-chamber implantable cardioverter defibrillator. The trial is called Inhibition of Unnecessary Right Ventricular Pacing with AV Search Hysteresis in implantable defibrillators (INTRINSIC RV).

"Guidant has long recognized that minimizing unnecessary device therapy, especially unnecessary right ventricular pacing, is a clinical imperative. Since June 2000, all Guidant dual-chamber implantable defibrillators include a proprietary feature called AV Search Hysteresis," said Joseph Smith, M.D., Ph.D., FACC, chief medical officer, Cardiac Rhythm Management, Guidant Corporation. "The INTRINSIC RV study is designed to bring forth scientific evidence of just how successful this feature is at minimizing unnecessary right ventricular pacing while preserving all of the benefits of dual chamber diagnosis and therapy."

A dual-chamber implantable cardioverter defibrillator can pace and/or sense in two chambers of the heart. One lead is placed in the right atrium (upper chamber); the other is placed in the right ventricle (lower chamber). Dr. Brian Olshansky yesterday presented an abstract of the INTRINSIC trial at the Heart Failure Society of America conference in Toronto, Canada.

"Unnecessary right ventricular pacing is a challenge for physicians," said Brian Olshansky, M.D., professor of Electrophysiology at the University of Iowa and principal investigator of INTRINSIC RV. "Single chamber implantable defibrillators can reduce unnecessary right ventricular pacing, however, I want my patients to receive all the benefits of a more sophisticated dual-chamber implantable defibrillator."

INTRINSIC RV is a multicenter, randomized trial including more than 1,500 patients at 114 centers in the United States, Germany, Italy and Australia. The trial evaluates Guidant-exclusive technology to reduce unnecessary right ventricular pacing in dual-chamber implantable cardioverter defibrillators. The AV Search Hysteresis function included in Guidant implantable cardioverter defibrillators prevents right ventricular pacing if the heart's natural rhythm is detected. The INTRINSIC RV study, launched in May of 2003, uses the Guidant VITALITY(R) AVT system. Guidant expects to report full results in mid 2005.

About Guidant

Guidant Corporation is a world leader in the treatment of cardiac and vascular disease. The company pioneers lifesaving technology, giving an opportunity for better life today to millions of cardiac and vascular patients worldwide. Driven by a strong entrepreneurial culture of 12,000 employees, Guidant develops, manufactures and markets a broad array of products and services that enable less invasive care for some of life's most threatening medical conditions.

NOTE TO MEDIA: For more information about Guidant, including its products and services, please visit the company's newsroom at www.guidant.com/newsroom.
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Sep 14, 2004
Words:505
Previous Article:Iptel Global, Inc. Announces New Strategic Direction and Management Changes.
Next Article:Top Business Leaders from the Outdoor Industry Endorse Kerry-Edwards; The Health of the Great American Outdoors is at Stake.
Topics:


Related Articles
Guidant Completes Enrollment Of Paclitaxel Drug-Eluting Stent U.S. Trial; Clinical Trial Fully Enrolled In Less Than Four Months.
New National Registry Will Study Left Ventricular Dysfunction in 100,000 Patients.
St. Jude Medical Sponsored Multicenter PAVE Study Completes Minimum Enrollment Requirements.
Guidant Announces First Implant in New Heart Failure Scientific Study; U.S. Study Continues Guidant's Leadership in Clinical Science.
Guidant Sponsored Clinical Trials in Spotlight at North American Society of Pacing and Electrophysiology Annual Meeting; Landmark Trials Featured.
Guidant-Sponsored Implantable Defibrillator Trials Result in Expanded Medicare Coverage; CMS Decision Leaves Some Seniors Without Coverage for Now.
Guidant Announces U.S. Approval of Newest Implantable Defibrillator for the Treatment of Irregular Heart Rhythms.
Guidant Announces Completion of Enrollment in SPIRIT FIRST Everolimus Eluting Stent Trial; Important Milestone Achieved in Guidant's Everolimus...
Guidant Begins Enrollment in European Drug Eluting Stent Study; Data From Study Will Support Launch of XIENCE V Coronary Stent System Outside the...
Guidant Receives FDA Approval to Expand U.S. Drug Eluting Stent Trial; Approval Sufficient for Completion of Pivotal Trial.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters